UiPath Inc.
PATH has repaired execution and rebuilt margin credibility, but at 30.22x P/E and 5.68x sales on only 5.0% FY2026 revenue growth, the stock already discounts much of the AI and margin recovery story.
PATH is no longer the broken execution story it was in 2024. The numbers now show a company that has stabilized go-to-market, rebuilt margin discipline, and found a credible AI monetization lane. Q4 revenue reached $481M, up 14% y/y, ARR hit $1.853B, up 11%, and management guided FY27 to $1.754B-$1.759B of revenue and $2.051B-$2.056B of ARR. The margin trajectory matters just as much. Q4 EBITDA margin was 20.8%, up roughly 1,370 bps from Q1, and management raised the long-term non-GAAP operating margin target to 30%. That is the profile of a business moving from recovery into harvest.
The problem is that the stock is already paying for that recovery. FY2026 revenue grew only 5.0%, EPS was $0.52, down 60.0% y/y, and the shares still trade at 30.22x P/E and 5.68x sales. That is a steep premium to peers at 13.1x earnings and 3.4x sales, especially when comparability is weak and peer dispersion is wide. The market can justify a premium if UiPath sustains double-digit ARR growth, converts AI adoption into meaningful incremental revenue, and keeps expanding margins. But if even one of those three pillars softens, the valuation has room to compress faster than fundamentals improve.
The core debate is whether AI widens or narrows PATH's moat. The bullish read is straightforward: AI product ARR is already nearly $200M, and 90% of $1M+ ARR customers use AI products, which suggests UiPath has become more than legacy RPA. If it becomes the orchestration layer for enterprise agents and workflows, today's multiple can hold. The bearish read is just as real: agentic automation lowers barriers for adjacent vendors, and hyperscalers can bundle enough capability to pressure stand-alone pricing over time. That keeps conviction from moving to BUY.
At $15.22, the setup is balanced. The company deserves more respect than it did two years ago, but not a blank check. A move to BUY would require evidence that AI ARR is scaling fast enough to bend consolidated growth above the current FY27 path without giving back margin. A move to SELL would require either a miss against the $2B+ ARR path or signs that the premium multiple is being defended only by buybacks and narrative rather than demand.
AI ARR scales well above nearly $200M, large-deal momentum stays strong, and investors underwrite the new 30% long-term margin target earlier.
Execution stays solid, PATH reaches the guided $2B+ ARR milestone, but valuation remains capped by only moderate revenue growth and rich multiples.
ARR growth cools below the FY27 path, margin gains fail to offset slower seat expansion, and the premium multiple compresses toward software peers.
Quant call aligns with analyst consensus (Hold: 1 buy / 8 hold / 1 sell).
You have power over your mind — not outside events. Realize this, and you will find strength.
FY27 points to a better earnings power profile than trailing FY2026 suggests, with revenue guided to $1.754B-$1.759B, non-GAAP operating income at ~$415M, and adjusted free cash flow at ~$425M, so the business is clearly improving faster than the trailing -8.9% operating margin implies. The issue is that the stock already prices in a lot of that recovery, with a 30.22x P/E that sits far above the 13.1x peer average even before giving full credit to AI monetization. The moat is stronger today than in 2024 because UiPath has embedded automation workflows, a large enterprise installed base, and AI attach rates that are now measurable, but over 3 to 5 years AI is also the main threat because copilots, platform vendors, and lower-code automation could compress pricing and narrow differentiation. Regulation is a second-order issue outside of federal procurement timing, while the bigger secular question is whether PATH becomes a durable orchestration layer for agentic workflows or just one automation tool in a more crowded stack.
- FY27 guidance implies revenue of $1.754B-$1.759B, up roughly 10% from FY2026's $1.6B, with ARR guided to $2.051B-$2.056B from $1.853B in Q4.
- Profitability is improving fast, with Q4 EBITDA margin 20.8%, up about 1,370 bps from 7.1% in Q1, and management lifting the long-term non-GAAP operating margin target to 30%.
- Valuation remains rich at 30.22x P/E and 5.68x P/S versus peer averages of 13.1x and 3.4x, while the quant price target is only $16.11, or 5.9% above $15.22.
- Recent execution is materially better: PATH beat the high end of guidance across all Q4 metrics, posted $481M revenue, 14% y/y growth, and generated $70M of net new ARR.
- AI adoption is becoming real revenue, not just messaging. AI product ARR reached nearly $200M, and 90% of customers with $1M+ ARR use AI products.
- Cloud transition is scaling, with Cloud ARR above $1.2B, up more than 20% y/y. That supports durability of the installed base even though it creates a near-term revenue recognition headwind.
- Capital return is meaningful. The company completed a $1B repurchase program and added $500M of new authorization, against a market cap of $5.6B.
- FY2026 still showed only 5.0% revenue growth and EPS of $0.52, down 60.0% y/y. That is not an obvious setup for a stock trading at 30.22x earnings.
- Management itself flags a ~1% FY27 revenue growth headwind from SaaS mix and assumes a variable macro and federal environment, which matters because the market is paying for acceleration now.
- The stock setup is crowded and fragile, with 28.75% short interest, negative near-dated options gamma, and spot only 2.93% above the $15.63 zero-gamma level after a -16.14% 1-week move.
- Peer-based valuation support is weaker than it looks because the comp set is messy and dispersion is wide at 7.9x average P/E spread, which makes a premium multiple harder to defend if growth softens even modestly.
| Metric | Value | Context |
|---|---|---|
| Current price | $15.22 | Reference point for valuation and scenario framing |
| Quant price target | $16.11 | 5.9% above current, High confidence, baseline call HOLD |
| FY2026 revenue | $1.6B | 5.0% YoY growth |
| FY2026 EPS | $0.52 | -60.0% YoY |
| Operating margin | -8.9% | Improved from -11.4% in the prior fiscal year |
| Net margin | -3.1% | Still modest despite first year of GAAP profitability on management commentary |
| Valuation | P/E 30.22x | P/S 5.68x | P/B 4.99x | Above peer averages of 13.1x P/E and 3.4x P/S |
| Q4 FY2026 revenue and EBITDA | $481M revenue | $0.10B EBITDA | EBITDA margin 20.8%, up about 60 bps vs Q4 and 1,370 bps vs Q1 |
| ARR | $1.853B | Q4 ARR, up 11% YoY; FY27 guide $2.051B-$2.056B |
| FY27 guidance | $1.754B-$1.759B revenue | ~$415M non-GAAP op income | ~$425M adj. FCF | Implies continued growth with margin expansion |
| Balance sheet and cash flow | Debt/Equity 0.04 | Debt/EBITDA 0.71 | Current ratio 2.20 | FCF $0.1B | Low leverage and adequate liquidity |
| Price action | 1W -16.14% | 3M +42.91% | -23.3% vs 52-week high | Still 18.1% above 200-day average of $12.89 |
The biggest risk is that FY27 revenue growth lands closer to the guided pace while valuation stays elevated at 30.22x P/E and 5.68x sales, leaving little room if AI monetization or federal demand slips.
The next catalyst is the December 2, 2026 earnings report, where investors need to see Q1 FY27 land near the high end of $395M-$400M revenue and confirm ARR tracking toward $2.051B-$2.056B for FY27.
Ownership is concentrated enough to matter, with the top three institutions holding 47.7% and insiders owning 6.5%. Short interest is very high at 28.75%, or 117.9M shares, though it fell 3% and days-to-cover is only 3.3, which points to active skepticism but not a trapped short base. Near-dated options positioning is unhelpful, with negative gamma and a zero-gamma level at $15.63, just 2.93% above spot, which can amplify downside if the stock trades weakly around earnings follow-through.
Core demand indicator, up 11% y/y, with FY27 ARR guided to $2.051B-$2.056B.
Growing over 20% y/y and increasing SaaS mix, which improves recurring quality but creates a ~1% FY27 revenue growth headwind.
Fastest strategic layer, with 90% penetration among $1M+ ARR customers.
No geography breakout was supplied, so the analysis leans on enterprise demand trends and federal exposure commentary instead.
FY27 guide implies continued ARR growth past $2B with margin expansion intact.
Management looks materially more credible today than it did on the 2025 Q1 call, when it cut FY25 revenue guidance to $1.405B-$1.410B, guided Q2 operating income to roughly breakeven, and admitted large multi-year deals had slipped amid compensation and execution issues. Since then, PATH delivered FY2026 revenue of $1.6B, improved operating margin to -8.9% from -11.4%, achieved its first year of GAAP profitability, and exited Q4 with $481M revenue, $1.853B ARR, and a 20.8% EBITDA margin. The earnings record also improved meaningfully, with beats in 7 of the last 8 reported quarters, including +87.5% on 2025-09-04 and +20.0% on 2026-03-11, offset by one miss of -5.9% on 2026-05-28 and only a slim +1.0% beat most recently. Product and strategy direction did not whipsaw either: the 2025 call pointed to Autopilot rollouts and sales-comp repair, while the current call shows AI product ARR at nearly $200M, strong large-deal momentum, and a higher 30% long-term margin target. That is not flawless execution, but it is a clear recovery from the 2024 stumble.
We delivered another strong quarter, beating the high end of our guidance across all metrics and closing out a year of disciplined execution.
As we look ahead, we expect to cross $2 billion in ARR this fiscal year, a milestone that reflects the durability of what we have built and the expanding role we play in how enterprises operate.
For the first fiscal quarter 2027, we expect revenue in the range of $395 million to $400 million, ARR in the range of $1.894 billion to $1.899 billion, non-GAAP operating income of approximately $80 million.
For the full fiscal year 2027, we expect revenue in the range of $1.754 billion to $1.759 billion, ARR in the range of $2.051 billion to $2.056 billion, non-GAAP operating income of approximately $415 million.
Given the strength and scalability of our model, we are updating our long-term non-GAAP operating margin target to 30%.
UiPath's moat sits in embedded enterprise workflows, installed-basis switching costs, and the breadth of automation use cases that sit across departments rather than in a single app. The evidence that this still matters is the $1.853B ARR base, $70M of Q4 net new ARR, and high AI adoption in large accounts, with 90% of $1M+ ARR customers using AI products. Durability is good but not absolute because the next 3 to 5 years bring heavier competition from hyperscalers, copilots, and adjacent automation vendors, so the moat must be reinforced by execution and product breadth rather than assumed permanent.
Capital allocation has been shareholder-friendly and fairly disciplined. PATH generated $0.1B of FY2026 free cash flow, spent $0.2B on buybacks, completed a prior $1B repurchase program, and authorized another $500M, while capex was effectively $0.0B and dividends remain $0.0B. The WorkFusion acquisition was described as immaterial, which suggests management is not stretching the balance sheet on large M&A while the core platform still needs internal product investment.
Rated HOLD, High conviction. UiPath has fixed a lot, and the business trajectory is better than the trailing FY2026 numbers make it look. But the stock is no longer cheap enough to ignore the gap between a strong narrative and only moderate full-year growth, especially with valuation at 30.22x earnings and a quant target of $16.11. A better entry, or proof that AI can push growth above the current FY27 path while preserving the new margin framework, would change the call. A clean break below that execution path would make the premium hard to defend.
≣ Full research note tap to expand
Executive Summary
HOLD, High conviction. PATH rates a HOLD at High conviction. The business is in better shape than it was two years ago, with Q4 revenue up 14%, ARR at $1.853B, a first year of GAAP profitability, and FY27 guidance calling for $1.754B-$1.759B revenue, $2.051B-$2.056B ARR, and ~$425M of adjusted free cash flow. The problem is price versus pace: after a 42.91% move in three months, the shares still trade above the quant base value, at a premium to peers on both earnings and sales despite modest full-year growth and a still-variable federal backdrop.
Investment Thesis
PATH is no longer the broken execution story it was in 2024. The numbers now show a company that has stabilized go-to-market, rebuilt margin discipline, and found a credible AI monetization lane. Q4 revenue reached $481M, up 14% y/y, ARR hit $1.853B, up 11%, and management guided FY27 to $1.754B-$1.759B of revenue and $2.051B-$2.056B of ARR. The margin trajectory matters just as much. Q4 EBITDA margin was 20.8%, up roughly 1,370 bps from Q1, and management raised the long-term non-GAAP operating margin target to 30%. That is the profile of a business moving from recovery into harvest.
The problem is that the stock is already paying for that recovery. FY2026 revenue grew only 5.0%, EPS was $0.52, down 60.0% y/y, and the shares still trade at 30.22x P/E and 5.68x sales. That is a steep premium to peers at 13.1x earnings and 3.4x sales, especially when comparability is weak and peer dispersion is wide. The market can justify a premium if UiPath sustains double-digit ARR growth, converts AI adoption into meaningful incremental revenue, and keeps expanding margins. But if even one of those three pillars softens, the valuation has room to compress faster than fundamentals improve.
The core debate is whether AI widens or narrows PATH's moat. The bullish read is straightforward: AI product ARR is already nearly $200M, and 90% of $1M+ ARR customers use AI products, which suggests UiPath has become more than legacy RPA. If it becomes the orchestration layer for enterprise agents and workflows, today's multiple can hold. The bearish read is just as real: agentic automation lowers barriers for adjacent vendors, and hyperscalers can bundle enough capability to pressure stand-alone pricing over time. That keeps conviction from moving to BUY.
At $15.22, the setup is balanced. The company deserves more respect than it did two years ago, but not a blank check. A move to BUY would require evidence that AI ARR is scaling fast enough to bend consolidated growth above the current FY27 path without giving back margin. A move to SELL would require either a miss against the $2B+ ARR path or signs that the premium multiple is being defended only by buybacks and narrative rather than demand.
Key Metrics
| Metric | Value | Context | |||
|---|---|---|---|---|---|
| Current price | $15.22 | Reference point for valuation and scenario framing | |||
| Quant price target | $16.11 | 5.9% above current, High confidence, baseline call HOLD | |||
| FY2026 revenue | $1.6B | 5.0% YoY growth | |||
| FY2026 EPS | $0.52 | -60.0% YoY | |||
| Operating margin | -8.9% | Improved from -11.4% in the prior fiscal year | |||
| Net margin | -3.1% | Still modest despite first year of GAAP profitability on management commentary | |||
| Valuation | P/E 30.22x | P/S 5.68x | P/B 4.99x | Above peer averages of 13.1x P/E and 3.4x P/S | |
| Q4 FY2026 revenue and EBITDA | $481M revenue | $0.10B EBITDA | EBITDA margin 20.8%, up about 60 bps vs Q4 and 1,370 bps vs Q1 | ||
| ARR | $1.853B | Q4 ARR, up 11% YoY; FY27 guide $2.051B-$2.056B | |||
| FY27 guidance | $1.754B-$1.759B revenue | ~$415M non-GAAP op income | ~$425M adj. FCF | Implies continued growth with margin expansion | |
| Balance sheet and cash flow | Debt/Equity 0.04 | Debt/EBITDA 0.71 | Current ratio 2.20 | FCF $0.1B | Low leverage and adequate liquidity |
| Price action | 1W -16.14% | 3M +42.91% | -23.3% vs 52-week high | Still 18.1% above 200-day average of $12.89 |
Financial Strength
The balance sheet is not the issue here. Leverage is low at 0.04 debt/equity and 0.71 debt/EBITDA, liquidity is solid with a 2.20 current ratio, and the company is still generating positive free cash flow at $0.1B despite a trailing -8.9% operating margin. The more important read is operating leverage: Q4 EBITDA margin at 20.8% and FY27 adjusted free cash flow guidance of ~$425M show a business with far better cash conversion than GAAP optics alone suggest. That financial strength gives management flexibility on buybacks and selective M&A, but it does not erase the fact that the equity already capitalizes much of the margin recovery.
Competitive Position
UiPath's moat sits in embedded enterprise workflows, installed-basis switching costs, and the breadth of automation use cases that sit across departments rather than in a single app. The evidence that this still matters is the $1.853B ARR base, $70M of Q4 net new ARR, and high AI adoption in large accounts, with 90% of $1M+ ARR customers using AI products. Durability is good but not absolute because the next 3 to 5 years bring heavier competition from hyperscalers, copilots, and adjacent automation vendors, so the moat must be reinforced by execution and product breadth rather than assumed permanent.
Management & Guidance
Current guidance is credible but not loose. Management guided Q1 FY27 revenue to $395M-$400M, ARR to $1.894B-$1.899B, and non-GAAP operating income to ~$80M, then set FY27 at $1.754B-$1.759B revenue, $2.051B-$2.056B ARR, ~$415M non-GAAP operating income, and ~$425M adjusted free cash flow. That outlook came after Q4 beat the high end of guidance across all metrics and follows an earnings pattern with 7 beats in 8 quarters, which supports management's regained credibility. The caution is that the latest outlook still bakes in a variable macro and federal environment plus a ~1% growth headwind from SaaS mix, so the guide is better read as achievable rather than conservative.
Segment Analysis
- ARR ($1.853B exiting Q4 FY2026): Core demand indicator, up 11% y/y, with FY27 ARR guided to $2.051B-$2.056B.
- Cloud ARR (over $1.2B): Growing over 20% y/y and increasing SaaS mix, which improves recurring quality but creates a ~1% FY27 revenue growth headwind.
- AI products (nearly $200M ARR): Fastest strategic layer, with 90% penetration among $1M+ ARR customers.
- Geography (not disclosed in provided data): No geography breakout was supplied, so the analysis leans on enterprise demand trends and federal exposure commentary instead.
Capital Allocation
Capital allocation has been shareholder-friendly and fairly disciplined. PATH generated $0.1B of FY2026 free cash flow, spent $0.2B on buybacks, completed a prior $1B repurchase program, and authorized another $500M, while capex was effectively $0.0B and dividends remain $0.0B. The WorkFusion acquisition was described as immaterial, which suggests management is not stretching the balance sheet on large M&A while the core platform still needs internal product investment.
Management Execution & Track Record
Management looks materially more credible today than it did on the 2025 Q1 call, when it cut FY25 revenue guidance to $1.405B-$1.410B, guided Q2 operating income to roughly breakeven, and admitted large multi-year deals had slipped amid compensation and execution issues. Since then, PATH delivered FY2026 revenue of $1.6B, improved operating margin to -8.9% from -11.4%, achieved its first year of GAAP profitability, and exited Q4 with $481M revenue, $1.853B ARR, and a 20.8% EBITDA margin. The earnings record also improved meaningfully, with beats in 7 of the last 8 reported quarters, including +87.5% on 2025-09-04 and +20.0% on 2026-03-11, offset by one miss of -5.9% on 2026-05-28 and only a slim +1.0% beat most recently. Product and strategy direction did not whipsaw either: the 2025 call pointed to Autopilot rollouts and sales-comp repair, while the current call shows AI product ARR at nearly $200M, strong large-deal momentum, and a higher 30% long-term margin target. That is not flawless execution, but it is a clear recovery from the 2024 stumble.
Positioning & Flows
Ownership is concentrated enough to matter, with the top three institutions holding 47.7% and insiders owning 6.5%. Short interest is very high at 28.75%, or 117.9M shares, though it fell 3% and days-to-cover is only 3.3, which points to active skepticism but not a trapped short base. Near-dated options positioning is unhelpful, with negative gamma and a zero-gamma level at $15.63, just 2.93% above spot, which can amplify downside if the stock trades weakly around earnings follow-through.
Bull Case
- Recent execution is materially better: PATH beat the high end of guidance across all Q4 metrics, posted $481M revenue, 14% y/y growth, and generated $70M of net new ARR.
- AI adoption is becoming real revenue, not just messaging. AI product ARR reached nearly $200M, and 90% of customers with $1M+ ARR use AI products.
- Cloud transition is scaling, with Cloud ARR above $1.2B, up more than 20% y/y. That supports durability of the installed base even though it creates a near-term revenue recognition headwind.
- Capital return is meaningful. The company completed a $1B repurchase program and added $500M of new authorization, against a market cap of $5.6B.
Bear Case
- FY2026 still showed only 5.0% revenue growth and EPS of $0.52, down 60.0% y/y. That is not an obvious setup for a stock trading at 30.22x earnings.
- Management itself flags a ~1% FY27 revenue growth headwind from SaaS mix and assumes a variable macro and federal environment, which matters because the market is paying for acceleration now.
- The stock setup is crowded and fragile, with 28.75% short interest, negative near-dated options gamma, and spot only 2.93% above the $15.63 zero-gamma level after a -16.14% 1-week move.
- Peer-based valuation support is weaker than it looks because the comp set is messy and dispersion is wide at 7.9x average P/E spread, which makes a premium multiple harder to defend if growth softens even modestly.
Valuation & Price Target
Engine price target $16.11 (+5.9% vs current), High confidence.
- P/E Multiple: $13.19 (28% weight)
- P/S Multiple: $16.67 (20% weight)
- Quality-adjusted: $17.29 (20% weight)
- DCF: $23.54 (6% weight)
The rating stays aligned with the quant baseline HOLD, and the agreement is mostly about valuation discipline rather than skepticism on the business. The engine's $16.11 target is only 5.9% above the current $15.22, while PATH trades at 30.22x P/E and 5.68x P/S against peer averages of 13.1x and 3.4x. The business absolutely looks better, with FY27 guidance for $1.754B-$1.759B revenue, ~$415M non-GAAP operating income, and ~$425M adjusted free cash flow, but that improvement is not enough to support a stronger rating after a 42.91% three-month run and with comps carrying a 7.9x dispersion that weakens peer-multiple precision. Sell-side consensus also sits at Hold, but that is only a loose cross-check, not part of the core call.
Risk Assessment
Risk score 42/100 (Moderate). The biggest risk is that FY27 revenue growth lands closer to the guided pace while valuation stays elevated at 30.22x P/E and 5.68x sales, leaving little room if AI monetization or federal demand slips.
The Bottom Line
Rated HOLD, High conviction. UiPath has fixed a lot, and the business trajectory is better than the trailing FY2026 numbers make it look. But the stock is no longer cheap enough to ignore the gap between a strong narrative and only moderate full-year growth, especially with valuation at 30.22x earnings and a quant target of $16.11. A better entry, or proof that AI can push growth above the current FY27 path while preserving the new margin framework, would change the call. A clean break below that execution path would make the premium hard to defend.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr